HSIC.VI Stock Analysis
HS
Avoid
Based on Eyestock quantitative analysis, HSIC.VI`s fundamental data and valuation indicate an investment grade of Avoid at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Greatly overvalued
Henry Schein, Inc. engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. The company is headquartered in Melville, New York and currently employs 22,000 full-time employees. The Company’s segments include Health care distribution and Technology and value-added services. The Health care distribution segment is combining its global dental and medical businesses, distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, dental specialty products (including implant, orthodontic and endodontic products), diagnostic tests, infection-control products, personal protective equipment products (PPE) and vitamins. The Technology and value-added services segment provides software, technology and other value-added services to healthcare practitioners. The firm distributes its products from approximately 29 located distribution centers.